You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》大和上调泰格医药(03347.HK)目标价至170元 评级「跑赢大市」
阿思达克 04-30 09:45
大和发表研究报告,引述泰格医药(03347.HK)管理层指,今年多区域临床试验(MRCTs)及实验室服务业务显着复苏,收入增长胜整体,估计公司全年收入可按年增长31.2%。

报告指出,在去年低基数效应下,今年两项主要业务收入增长表现强劲,当中新冠相关项目高需求带动下,首季MRCTs新增订单额已超越去年全年水平,预期收购方达後,今年余下时间实验室服务可维持高速增长,收入料按年升40%,并於今、明两年维持约35%至40%的增速。

该行指出,公司内地新生产设施预期於下半年投运,预测今年全年盈利将增长69.2%,较早前预测的63.3%有所提升,并将2021至2023年每股盈测提升4%至7%,目标价由160元升至170元,维持「跑赢大市」评级。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account